FDA Approves Tukysa for Advanced HER2+ BC

Moderators

Have you been diagnosed with advanced-stage HER2-positive breast cancer that has been treated with at least once anti-HER2 regimen and are considering which treatments to try next? On April 17, 2020, the FDA approved Tukysa (chemical name: tucatinib) in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer or locally-advanced HER2-positive disease that can't be completely removed with surgery.

Read the breaking news story here, and leave your comments below.

Read more about Tukysa (chemical name: tucatinib).

NOTE:

The HER2CLIMB-02 trial is enrolling people diagnosed with advanced-stage HER2-positive breast cancer

The HER2CLIMB-02 trial (https://clinicaltrials.gov/ct2/show/NCT03975647) is looking to see if Tukysa (chemical name: tucatinib) given in combination with Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) will offer more benefits than Kadcyla alone in people diagnosed with:

• metastatic HER2-positive breast cancer
• locally-advanced HER2-positive disease that can't be completely removed with surgery

• • a taxane chemotherapy, such as Taxotere (chemical name: docetaxel) or Taxol (chemical name: paclitaxel)
• • Herceptin (chemical name: trastuzumab)

The HER2CLIMB-02 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit www.her2climb.com.

For more information on detailed eligibility requirements or to enroll

Visit the http://www.her2climb.com/">HER2CLIMB-02 trial site. You also may email clinicaltrials@seagen.com or call 1-866-333-7436.

ShetlandPony

This is tucatinib.

Moderators

Yes -- thank you ShetlandPony -- we will edit our post to clarify!

Topacio

Hi,

I was in the trial, HER2climb, but I was in the blind group.

So this coming May6, 2020, going to start again with the real drug tutacanib.

Hope everything will go smooth, I going to try to put as much info as I can

Thanks!!’

Moderators

Letting you all know, The HER2CLIMB-02 trial is enrolling people diagnosed with advanced-stage HER2-positive breast cancer

The HER2CLIMB-02 trial (https://clinicaltrials.gov/ct2/show/NCT03975647) is looking to see if Tukysa (chemical name: tucatinib) given in combination with Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) will offer more benefits than Kadcyla alone in people diagnosed with:

• metastatic HER2-positive breast cancer
• locally-advanced HER2-positive disease that can't be completely removed with surgery

• • a taxane chemotherapy, such as Taxotere (chemical name: docetaxel) or Taxol (chemical name: paclitaxel)
• • Herceptin (chemical name: trastuzumab)

The HER2CLIMB-02 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit www.her2climb.com.

For more information on detailed eligibility requirements or to enroll

Visit the http://www.her2climb.com/. You also may email clinicaltrials@seagen.com or call 1-866-333-7436